Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant hormonal therapy for extensive ductal carcinoma in situ
2020-003575-18Phase 2Terminated
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Oct 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tamoxifen and anastrozole in ductal carcinoma in situ (DCIS) and Breast carcinoma in situ (BCIS) (2 arms), sponsored by Institut Cancérologique de l'Ouest. Started Oct 2020; status: terminated.
02
Drugs
tamoxifenanastrozole
03
Conditions
ductal carcinoma in situ (DCIS)Breast carcinoma in situ (BCIS)
Beyond the preview
Go deeper on 2020-003575-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003575-18.